ORIGINAL ARTICLE Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents Samantha M. Olson, Margaret M. Newhams, Natasha B. Halasa, et al N Engl J Med 2022; 386:713-723DOI: 10.1056/NEJMoa2117995 Abstract BACKGROUND The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United...

Original Investigation November 17, 2021 Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant: A Randomized Clinical Trial Kamrouz Ghadimi, Jhaymie Cappiello, Mary Cooter-Wright, et al JAMA Surg. 2022;157(1):e215856. doi:10.1001/jamasurg.2021.5856 Abstract Importance  Inhaled nitric oxide (iNO) is commonly administered for selectively inhaled pulmonary vasodilation and prevention of oxidative injury after lung transplant (LT). Inhal...

Original Investigation January 18, 2022 Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial Jeffrey S. Berger, Lucy Z. Kornblith, Michelle N. Gong, et al JAMA. 2022;327(3):227-236. doi:10.1001/jama.2021.23605 Abstract Importance  Platelets represent a potential therapeutic target for improved clinical...

ARTICLES|ONLINE FIRST Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021 COVID-19 National Preparedness Collaborators Lancet Published:February 01, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00172-6 Summary Background National rates of COVID-19 infection and fatality have varied dramatically since the o...

ARTICLES|ONLINE FIRST Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group Lancet Infect Dis Published:December 23, 2021DOI:https://doi.org/10.1016/S1473-3099(21)00751-9 Summary Background We aimed to assess the efficacy and safety of two neutralising mono...

ARTICLES| VOLUME 399, ISSUE 10325, P665-676, FEBRUARY 12, 2022 Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet 2022; 399: 665-676 Summary Background Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, ...

ARTICLES|ONLINE FIRST Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis Manoj V Maddali, Matthew Churpek, Tai Pham, et al Lancet Respir Med Published:January 10, 2022DOI:https://doi.org/10.1016/S2213-2600(21)00461-6 Summary Background Two acute respiratory distress syndrome (ARDS) subphenotypes (hyperinflammatory and hypoinflammatory) with distinct...

ORIGINAL ARTICLE Endovascular Therapy for Acute Stroke with a Large Ischemic Region Shinichi Yoshimura, Nobuyuki Sakai, Hiroshi Yamagami, et al N Engl J Med February 9, 2022DOI: 10.1056/NEJMoa2118191 Abstract BACKGROUND Endovascular therapy for acute ischemic stroke is generally avoided when the infarction is large, but the effect of endovascular therapy with medical care as compared with medical care alone for large strokes has not been well studie...

ORIGINAL ARTICLE Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 Ariel Hammerman, Ruslan Sergienko, Michael Friger, et al N Engl J Med February 16, 2022DOI: 10.1056/NEJMoa2119497 Abstract BACKGROUND The risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) decreases substantially among patients who have recovered from coronavirus disease 2019 (Covid-19). However, it is unknown how long protective immunity ...

ARTICLES|ONLINE FIRST Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial Benjamin A Fisher, Tonny Veenith, Daniel Slade, et al Lancet Respir Med Published:December 16, 2021DOI:https://doi.org/10.1016/S2213-2600(21)00460-4 Summary Background Dysregulated inflammation is associated with poor outcomes...